About Cliff Gorski

This author has not yet filled in any details.
So far Cliff Gorski has created 79 blog entries.

Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy

2019-04-26T09:40:11+00:00

Top-line data expected by end of 2019 NEWS PROVIDED BY Stealth BioTherapeutics  Apr 25, 2019, 16:15 ET BOSTON, April 25, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced completion of enrollment for MMPOWER-3 (SPIMM-301), with top-line data expected by year end. MMPOWER-3 is [...]

Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy2019-04-26T09:40:11+00:00

An Existing Drug May Have Therapeutic Potential in Mitochondrial Disease

2019-02-26T15:56:55+00:00

An Existing Drug May Have Therapeutic Potential in Mitochondrial Disease --CHOP Researchers: Animal Studies May Offer Clues to Possible Precision Medicine Approach--   Philadelphia, Feb. 26, 2019 --New preclinical findings from extensive cell and animal studies suggest that a drug already used for a rare kidney disease could benefit patients with some mitochondrial disorders—complex [...]

An Existing Drug May Have Therapeutic Potential in Mitochondrial Disease2019-02-26T15:56:55+00:00

NIH Funds Interdisciplinary Team Pursuing Better Mitochondrial Disease Diagnosis

2019-02-15T11:16:59+00:00

An interdisciplinary research team has been awarded $395,112 to develop new tools to assess mitochondrial diseases, which are difficult to diagnose and treat, and can be fatal in children and adults. The National Institutes of Health have awarded researchers from the College of Engineering and the J. William Fulbright College of Arts and Sciences [...]

NIH Funds Interdisciplinary Team Pursuing Better Mitochondrial Disease Diagnosis2019-02-15T11:16:59+00:00

UMDF supports NORD in campaign for Rare Disease Day

2019-01-22T14:27:09+00:00

UMDF supports The National Organization for Rare Disorders (NORD)Ⓡ, in their new campaign for Rare Disease Day centering on three simple words: Show Your Stripes.  The campaign is a call to action for people to literally and figuratively “show their stripes” in support of rare diseases leading up to and on Rare Disease Day, [...]

UMDF supports NORD in campaign for Rare Disease Day2019-01-22T14:27:09+00:00

Johns Hopkins Medicine & Kennedy Krieger named certified Mitochondrial Medicine Center

2018-12-20T08:10:49+00:00

Baltimore, MD , December 19, 2018 -- The Johns Hopkins University School of Medicine and Kennedy Krieger Institute have jointly been named a certified Mitochondrial Medicine Center (MMC). Mitochondrial disease affects tiny structures within the cell, called mitochondria, that are often called the "powerhouses" of the cell. The disease is inherited, and it causes [...]

Johns Hopkins Medicine & Kennedy Krieger named certified Mitochondrial Medicine Center2018-12-20T08:10:49+00:00

Foundations Combine To Provide A Larger Platform For Patient Community

2018-12-12T13:13:27+00:00

(Pittsburgh, PA)  -- The Foundation for Mitochondrial Medicine (FMM) and the United Mitochondrial Disease Foundation (UMDF) are excited to announce an agreement to combine and advance their synergistic missions of advancing research, education and patient support for treatments of mitochondrial disease.  FMM made this decision after careful strategic consideration for opportunities to generate greater [...]

Foundations Combine To Provide A Larger Platform For Patient Community2018-12-12T13:13:27+00:00

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy

2018-12-10T12:00:13+00:00

BOSTON, Dec. 10, 2018 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead investigational candidate, elamipretide, for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy. "We are pleased the FDA [...]

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy2018-12-10T12:00:13+00:00